Oct 20, 2021 10:35 AM (GMT+8) · EqualOcean
On October 19, insilico medicine, an end-to-end artificial intelligence drug R & D company, announced the appointment of Dr. Michelle Chen as the chief business officer to lead the company's strategy and business development activities. It is reported that before joining silicon intelligence, Dr. Michelle Chen served as senior vice president of enterprise development and R & D business development of Wuxi biology, leading a number of major mergers and acquisitions and licensing transactions.

This text is a result of machine translation.